Where does Forma Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Forma Therapeutics, Inc. ranks #3,096 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Forma Therapeutics, Inc. hold?

Forma Therapeutics, Inc. holds 122 US utility patents granted between 2016 and 2025, spanning 7 technology areas.

What is Forma Therapeutics, Inc.'s Innovation Score?

Forma Therapeutics, Inc. has an Innovation Score of 41.8 out of 100 (top 32% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Forma Therapeutics, Inc. focus on?

Forma Therapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 113 patents. Grants appear in 7 CPC subclasses total.

Is Forma Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Forma Therapeutics, Inc.'s recent grant velocity is -28% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Forma Therapeutics, Inc.'s patents?

Forma Therapeutics, Inc.'s patents average 22.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Forma Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Forma Therapeutics, Inc.

USPTO PatentsView assignee record - 122 granted patents across 7 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Forma ranks #3,096 of 49,997 tracked US assignees by granted-patent volume, with 122 patents across 7 technology areas.

#3,096
of 49,997 US assignees by volume: Top 32%
by Innovation Score (41.8/100): 22.9
avg claims per patent: -28%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3096 · US Corporation #3,096 · 122 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 122 grants
TOP-DECILE #3,096/49,997
PHOTO-FINISH CVS Pharmacy
CPC-NARROW C07D · 7 areas
INNOV-PAR 41.8/100
CLAIMS-DENSE 22.9 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -28% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: CVS Pharmacy, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Forma Therapeutics · this assignee

42
IQ-Analog · near

42
Land O'Lakes · near

42
Mawetal · near

42
Wako Pure Chemical… · near

42
3D Lighting… · lowest

7

What this shows Forma's Innovation Score is 41.8/100 (top 32% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Forma's grants concentrate

Forma Therapeutics, Inc. is a focused PatentsView assignee: 7 CPC subclasses with 92.6% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2019 (51 grants) versus a trough of 2 in 2016. By volume, Forma sits between CVS Pharmacy, Inc. and MAN Energy Solutions SE.

Forma's three-year grant acceleration

From 2019–2021 to 2022–2024, Forma Therapeutics, Inc. moved from 77 to 24 grants (0.31x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,987. See the growth leaderboard.

CVS Pharmacy

122
Ecco Sko A/S

122
Ewha University—I…

122
Early Warning Ser…

122
Faurecia Emission…

122
Hino Motors

122
Irdeto B V

122
MAN Energy Soluti…

122
Forma Therapeutics ◀

122

What this shows Forma holds 122 patents at rank #3,095, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Forma

By rank, the assignees closest to #3,095 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Forma's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Forma, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (42 here).

Land O'Lakes, Inc. 42 IQ-Analog Corporation 42 Wako Pure Chemical Industries, Ltd. 42 Mawetal LLC 42

Similar claim depth

Nearest assignees by average claims per patent (22.9 here).

Cardioinsight Technologies Inc. 22.9 avg Theatro Labs, Inc. 22.9 avg Versata Development Group, Inc. 22.9 avg Kala Pharmaceuticals, Inc. 22.9 avg

Forma's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 32% higher than 68% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Forma Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	2	1.6%
2017	9	7.4%
2018	7	5.7%
2019	51	41.8%
2020	15	12.3%
2021	11	9.0%
2022	11	9.0%
2023	9	7.4%
2024	4	3.3%
2025partial year	3	2.5%

Which technologies does Forma Therapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 113

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 112

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 61

Y02A - Technologies FOR Adaptation TO Climate Change 31

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

C07C - Acyclic OR Carbocyclic Compounds 6

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

Top 7 of 7 technology areas

Where it ranks

Overall rank by patents

#3,096

of 49,997 tracked assignees

Innovation Score

41.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Forma Therapeutics, Inc.'s patent record in context - here's where to go next.

Forma Therapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 92.6% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #3,096 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Forma Therapeutics, Inc. against CVS Pharmacy, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 41.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.